The atrophic phenotype of knee osteoarthritis (OA) is not associated with more rapid progression of disease when compared with the non-atrophic phenotype: The most study  by Crema, M.D. et al.
Table
Relation of incident bisphosphonate use to risk of incident KR among older women with incident knee OA
Analytic Approach Incident Bisphosphonate User Non-Bisphosphonate User Crude HR (95% CI) Adjusted HR* (95% CI)
PS*-matched
N 1964 1964
Mean OA duration 4.4 ± 3.5years 4,5 ± 3,5 years
Crude incidence rate per 1000 person-years 21.45 28.94 0.75 (0.59-0.94) 0.76 (0.61-0.96)
BMI-and age-matched
N 1869 5017
Mean OA duration 4.6 ± 3.5 years 3.1 ± 2,9 years
Crude incidence rate per 1000 person-years 24.37 60.62 0.40 (0.33-0,49) 0.40 (0.30-0.53)
*Variables included in PS model and included in the “Adjusted HR” model: 1) OA severity and duration 2) General (age, gender, BMI, socioeconomic status); 3) Comorbidities
(osteoporosis-related (osteoporosis, hip fracture, vertebral fracture, number of bone mineral density measurements), hypertension, diabetes (including severity), hyper-
lipemia, ischemic heart disease (including severity), heart failure, atrial ﬁbrillation, stroke, dementia/cognitive impairment, depression, seizure disorder, venous throm-
boembolism, chronic obstructive lung disease, pneumonia, renal disease, liver disease, cancers except skin cancer, cellulitis, falls, inﬂammatory arthritis, arid peptic ulcer
disease); 4) Habits (smoking status and alcohol use); 51 Health status (number of GP visits and hospitalization, albumin level); and 6) Medication use (Non-steroidal anti-
inﬂammatory medications, opioid or non-opioid analgesics, anti-hypertensive, cholesterol lowering, insulin/oral hypoglycemic, glucocorticoids (systemic and inhaled),
estrogens, and anti-epileptics)
Table 1
Differences between atrophic OA knees vs. non-atrophic OA knees regarding pro-
gression of JSN and progression of cartilage loss, using both (radiographic and MRI)








No progression 54/77 (70%) 224/373 (60%)
Slow progression 22/77 (29%) 143/373 (38%) 0.25









No progression 45/77 (58%) 171/373 (46%) 0.12
Slow progression 13/77 (17%) 91/373 (24%)








No progression 30/50 (60%) 248/400 (62%)
Slow progression 19/50 (38%) 146/400 (36%) 0.94








No Progression 29/50 (58%) 187/400 (47%)
Slow Progression 12/50 (24%) 92/400 (23%) 0.17
Fast Progression 9/50 (18%) 121/400 (30%)
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nate or bone-modulating therapy. We identiﬁed women who had
incident (ﬁrst) prescription of a bisphosphonate (i.e., alendronate,
etidronate-calcitonin, ibandronate, pamidronate, risedronate, zolendr-
onate) after their incident (new onset) knee OA diagnosis. We com-
puted propensity scores (PS) using logistic regression, with incident
bisphosphonate use as the dependent variable and potential con-
founders that reﬂect indication for bisphosphonate use and for KR
(Table) as the independent variables. Each incident bisphosphonate
user wasmatched 1:1 with an unexposed subject with greedymatching
using the PS within 1-year cohort accrual blocks. Follow-up started
from the index date (date of 1st bisphosphonate prescription for the
exposed, and randomly assigned to the unexposed within the one-year
accrual block), and continued until KR, death, censoring, or end of study.
The relation of incident bisphosphonate use to KR among women with
incident knee OA was assessed using Cox proportional hazard models.
Because body mass index (BMI) is an important confounder, we con-
ducted separate analyses in which incident bisphosphonate users were
matched by BMI (±0.5kg/m2) and age (same birth year) to up to 4
unexposed subjects, and variables used in the PS model were addi-
tionally adjusted for in this model.
Results: In the PS-matched approach, we identiﬁed 1964 incident
bisphosphonate users who were matched to 1964 non-users (mean age
76, mean BMI 27.4), withmean follow-up time of 3 years. Themean (SD)
age at incident knee OAdiagnosis was 72 (8), at incident bisphosphonate
prescription was 76 (8), and at KR was 75 (7). Overall, covariates were
well-balanced in the two groups. The crude incidence rate of KR among
incident bisphosphonate users was 21.45 per 1000 person-years, and
28.94 per 1000 person-years among the non-users. The PS-matched
model hazards ratio (HR)was 0.75 (95% CI 0.59-0.94).When additionally
adjusted for the potential confounders included in the original PSmodel,
the effect estimate remained unchanged (Table). In the BMI- and age-
matched cohort approach (N¼1869 incident users; 5017 matched non-
users), the effect estimates remained protective (Table).
Conclusions: In this large cohort of older women with incident knee
OA, those with incident bisphosphonate use had a lower risk of KR than
non-users. While we cannot rule-out potential for residual confounding
(e.g., confounding by indication) or possible depletion of susceptibles
(i.e., women who had a KR prior to incident bisphosphonate use were
excluded), these results suggest that bisphosphonates may have bene-
ﬁcial effects on knee OA.
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THE ATROPHIC PHENOTYPE OF KNEE OSTEOARTHRITIS (OA) IS NOT
ASSOCIATED WITH MORE RAPID PROGRESSION OF DISEASE WHEN
COMPARED WITH THE NON-ATROPHIC PHENOTYPE: THE MOST
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Purpose: In knees exhibiting fast progression of cartilage loss over time,
osteophyte formation may lag behind cartilage loss, which might thenmanifest as an atrophic phenotype of knee osteoarthritis (OA). Cases of
rapidly progressive OA were observed as a potential adverse event in
studies evaluating efﬁcacy of nerve growth factor inhibitors (aNGF). The
atrophic phenotype of OA is believed to be a predisposing entity tomore
rapid progression of OA. To support the hypothesis that atrophic OA is
associated with faster progression of disease, we assessed the associa-
tions of the presence of the atrophic phenotype of tibiofemoral OA at
baseline with progression of radiographic JSN and MRI progression of
cartilage loss over 30 months.
Methods:MOSTstudy participants with available OARSI grading system
scores of tibiofemoral JSN and osteophytes on radiographs (from 0 to 3),
tibiofemoralWORMS grades onMRI for cartilagemorphology (from 0 to
6) and osteophytes (from 0 to 7) for all ten subregions, as well as
WORMS grades on MRI for meniscal morphology (from 0 to 4) and
meniscal extrusion (from 0 to 3) bilaterally, performed at baseline and
30 months follow-up (FU), were included. Based on baseline radio-
graphs, the atrophic phenotype of tibiofemoral OAwas deﬁned as OARSI
grades 1 or 2 for JSN and grade 0 (absence) for osteophytes. Non-atro-
phic knee OA was deﬁned as OARSI grades 1 or 2 with osteophytes
grades 2 or 3. Based on baseline MRI, atrophic knee OA was deﬁned as
tibiofemoral severe cartilage damage (grades 5 or 6) in at least 1 of 10
subregions with absent or tiny osteophytes (grades 0 to 2) in all tibio-
femoral subregions. Regarding progression of JSN on radiographs from
baseline to FU, three groups were deﬁned: no progression (no increase
in OARSI grade in both tibiofemoral compartments), slow (an increase
Table 2
Association of atrophic knee OA with any progression of JSN and cartilage loss, compared to non-atrophic OA knees using both (radiographic and MRI) deﬁnitions of atrophic
and non-atrophic OA.
OA phenotype (Radiographic deﬁnition) Absence of progression of JSN Any progression of JSN Adjusted odds ratio
OR (95%CI) p-value
Non-atrophic OA 224/373 (60%) 149/373 (40%) 1.0 (ref)
Atrophic OA 54/77 (70%) 23/77 (3096) 0.6 (0.4, 1.0) 0.06
OA phenotype (Radiographic deﬁnition) Absence of progression of cartilage loss Any progression of cartilage loss Adjusted odds ratio
OR (95%CI) p-value
Non-atrophic OA 171/373 (46%) 202/373 (54%) 1.0 (ref) –
Atrophic OA 45/77 (58%) 32/77 (42%) 0.6 (0.3, 1.0) 0.04
OA Phenotype (MRI Deﬁnition)
Non-atrophic OA
Absence of Progression of JSN Any Progression of JSN Adjusted Odds Ratio
OR (95%CI) p-value
248/400 (62%) 152/450 (38%) 1.0 (ref) –
Atrophic OA 30/50 (60%) 20/50 (40%) 1.2 (0.7, 2.3) 0.53
OA Phenotype (MRI Deﬁnition) Absence of Progression of Cartilage Loss Any Progression of Cartilage Loss Adjusted Odds Ratio
OR (95%CI) p-value
Non-atrophic OA 187/400 (47%) 213/400(53%) 1.0 (ref) –
Atrophic OA 29/50 (58%) 21/50 (4296) 0.7 (0.4,1.3) 0.24
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gression (an increase of more than one OARSI grade in at least one
compartment). Regarding progression of cartilage loss on MRI from
baseline to FU, three groups were deﬁned: no progression (same
WORMS grade in all ten subregions), slow (an increase up to one
WORMS grade, including within-grade increase, in at least one of the
ten subregions), and fast progression (an increase of more than one
WORMS grade in at least one of the ten subregions). Co-variance
analysis was performed to test if there were differences between
atrophic vs. non-atrophic knee OA phenotypes, using both (radiographs
and MRI) deﬁnitions, regarding no progression, slow, and fast pro-
gression of JSN and cartilage loss. Logistic regression analysis with
generalized estimated equations was performed to assess the associa-
tion of atrophic knee OA with any progression of JSN and cartilage loss,
compared to non-atrophic OA knees (reference group). The results were
adjusted for age, gender, body mass index, tibiofemoral malalignment,
progression of meniscal damage and extrusion.
Results: A total of 450 knees from 398 participants were included.
Using the radiographic deﬁnition, therewere 77 (17.1%) atrophic OA and
373 (82.9%) non-atrophic OA knees at baseline. Using the MRI deﬁ-
nition, there were 50 (11.1%) atrophic OA and 400 (88.9%) non-atrophic
OA knees. There were no signiﬁcant differences between both groups
(atrophic vs. non-atrophic) regarding fast progression of JSN or cartilage
damage (Table 1). Logistic regression analysis using both deﬁnitions
showed that the atrophic phenotype of knee OA was not at increased
risk for progression of disease compared to the non-atrophic phenotype
(Table 2). Using the radiographic deﬁnition, a modest protective effect
against progression of MRI cartilage loss was demonstrated for atrophic
OA knees when compared to the non-atrophic group (OR ¼ 0.6 (95%CI
0.3, 1.0); p¼0.04).
Conclusions: Based on these results, the atrophic phenotype of knee OA
does not predispose OA joints to more rapid progression compared to
non-atrophic OA. This ﬁnding might be of potential relevance for eli-
gibility of participants with atrophic knee OA in aNGF programswho are
commonly excluded due to potential increased risk for rapid pro-
gressive OA.
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Purpose: Low-grade inﬂammationmayplaya role in osteoarthritis (OA).
Although some studies reported that inﬂammatorymarkers such as high
sensitivity C-reactiveprotein (hs-CRP)were increased inOA, theﬁndings
for associations between hs-CRP and OA are inconsistent. The link
between serum levels of hs-CRP and bone marrow lesions (BMLs) in OApatientshas not been explored., Similarly, the ﬁndings for the associa-
tions between resistin and OA are controversial and little is known if
resistin is associated with BMLs. The aims of this study were, therefore,
to describe the association between serum levels of hs-CRP, resistin and
BMLs cross sectionally and longitudinally in patients with knee OA.
Methods: A total of 188 patients (mean 63 years, range 50-79, female
53%) with symptomatic knee OA were selected from a randomised
placebo controlled clinical trial studying the effect of vitamin D sup-
plementation on OA. Serum levels of hs-CRP and resistin were tested at
baseline and 24 months later using enzyme-linked immunosorbent
assay (ELISA). T2 weighted fat-supressed fast spin echo magnetic res-
onance imaging (MRI) was performed at baseline and 24 months to
assess compartmental and total knee BMLs scores and their changes
using modiﬁed Whole-Organ MRI Score system (WORMS). Linear or
logistic regression analyses were used to determine the association of
baseline hs-CRP and resistin with total knee BMLs as well as changes or
increases in BMLs before and after adjustment for age, sex, BMI, treat-
ment (vitamin D / placebo) and CRP / resistin as appropriate.
Results: At baseline, quartiles of serum level of hs-CRP were associated
with total knee bonemarrow lesions in multivariable analyses (OR: 1.45
per quartile, 95% CI: 1.01, 2.09). Serum levels of resistin were associated
with total knee BMLs (b:0.04 per ng/ml, 95% CI: 0.01, 0.08). Longitudi-
nally, quartiles of serum levels of hs-CRP predicted increases in total
knee BMLs (OR: 1.51 per quartile, 95% CI: 1.08, 2.12; Figure 1), and
changes in serum levels of hs-CRP were associated with changes in total
knee BMLs (b: 0.09, 95% CI: 0.04, 0.34). Baseline resistin levels were not
signiﬁcantly associated with change in total BMLs. Change in serum
levels of resistin were only associated with changes in lateral tibiofe-
moral BMLs (b: 0.16, 95%CI: 0.01, 0.05) and not total knee BMLs (b: 1.01,
95%CI: 0.97, 1.04).
Conclusions: This is the ﬁrst study to report that serum levels of hs-CRP
are associated with total knee BMLs and predict worsening knee BMLs
over 2 years in patients with knee OA, suggesting inﬂammatory
involvement in the pathogenesis of BMLs. Serum resistin levels are
associated with BMLs in knee OA, but the causal relationship is
unknown.
